坐骨神経痛治療薬の世界市場:疫学予測

◆英語タイトル:Sciatica - Epidemiology Forecast to 2030
◆商品コード:DELV20JU223
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年6月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(223名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Sciatica – Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Sciatica epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan

Study Period: 2017-2030

Sciatica Understanding
Sciatica is a pain in the lower extremity resulting from irritation of the sciatic nerve. The pain of Sciatica is typically felt from the low-back (lumbar area) to behind the thigh and can radiate down below the knee. The sciatic nerve is the largest nerve in the body and begins from nerve roots in the lumbar spinal cord in the low back and extends through the buttock area to send nerve endings down the lower limb. Radiculopathy is sometimes referred to as sciatic nerve pain. Sciatica is an unbearable condition in which the patient experiences pain and/or paresthesia in the supply of the sciatic nerve or linked lumbosacral nerve root. Sciatica is a specific pain that is a direct result of sciatic nerve or sciatic nerve root pathology. The term sciatica is limited to the pain and irritation in nerve roots from L1 to L4 and may also involve related areas. Many times patients and clinicians use Sciatica to describe any pain arising from the lower back and radiating down to the leg.

There are some major risk factors associated with the patient for the initiation of the disease and further progression. Some of them are personal factors which involve that the peak age of the disease occurrence is between 45 and 64 years. Smoking and mental health are not only of the causes but also major factors for the progression of the disease. Occupational factors include strenuous physical activity, for example, frequent lifting, especially while bending and twisting. Driving, including vibration of the whole body can also be one of the minor factors.

Sciatica Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Sciatica, Diagnosed Prevalence of Sciatica, Cause-specific Diagnosed Prevalence of Sciatica, Gender-specific Diagnosed Prevalence of Sciatica, Age-specific Diagnosed Prevalence of Sciatica, Surgery eligible patient pool of Sciatica scenario of Sciatica in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Sciatica Detailed Epidemiology Segmentation
The total prevalent population of Sciatica in the seven major markets ranges was 27,022,660 in 2017
Delveinsight has also analyzed the diagnosed prevalent population of lumbar disc herniation. In 2017, the number of diagnosed prevalent cases of lumbar disc herniation was 7,358,250, which will increase in the forecast period.
In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States.
In 2017, the surgery eligible patient pool in the US was 1,082,736, which is anticipated to increase in the forecast period.
The age-specific prevalence of Sciatica was maximum in the age group 45–54 with 2,043,958 cases in 2017 in the US while the lowest number of cases were found in 18–34 age group with 1,218,199 cases in 2017.
In 2017, it was estimated that 4,802,485 males and 3,373,349 females were found with Sciatica in the United States. On the other hand, a similar trend is not observed in EU5, and Japan wherein females are more predominant than males.

Scope of the Report
The Sciatica report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
The Sciatica Epidemiology Report and Model provide an overview of the risk factors and global trends of Sciatica in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
The report provides insight about the historical and forecasted patient pool of Sciatica in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
The report assesses the disease risk and burden and highlights the unmet needs of Sciatica
The report provides the segmentation of the Sciatica epidemiology

Report Highlights
Eleven-Year Forecast of Sciatica
7MM Coverage
Prevalence of Sciatica
Diagnosed Prevalence of Sciatica
Cause-specific diagnosed prevalence of Sciatica
Gender-specific Diagnosed Prevalence of Sciatica
Age-specific Diagnosed Prevalence of Sciatica
Surgery eligible patient pool of Sciatica

KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Sciatica?
What are the key findings pertaining to the Sciatica epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
What would be the total number of patients of Sciatica across the 7MM during the forecast period (2017-2030)?
Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
What is the disease risk, burden and unmet needs of the Sciatica?
What are the currently available treatments of Sciatica?

Reasons to buy
The Sciatica Epidemiology report will allow the user to -
Develop business strategies by understanding the trends shaping and driving the global Sciatica market
Quantify patient populations in the global Sciatica market to improve product design, pricing, and launch plans
Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sciatica therapeutics in each of the markets covered
Understand the magnitude of Sciatica population by its epidemiology
The Sciatica Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

【レポートの目次】

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Sciatica Epidemiology Overview at a Glance

4.1 Patient Share (%) Distribution of Sciatica in 2017

4.2 Patient Share (%) Distribution of Sciatica in 2030

5 Disease Background and Overview: Sciatica

5.1 Introduction

5.2 Difference between Sciatica and Lower Back Pain

5.3 Symptoms of Sciatica

5.4 Causes of Sciatica

5.4.1 Spinal Disc Herniation

5.4.2 Spinal Stenosis

5.4.3 Pregnancy

5.4.4 Piriformis syndrome

5.4.5 Osteoarthritis

5.4.6 Spondylosis and spondylolisthesis

5.4.7 Nondiscogenic causes

5.5 Pathophysiology of disk-related Sciatica

5.5.1 Clinical observation

5.5.2 Physiologic Variants of Sciatica

5.6 Pathophysiological Mechanisms in Radicular Pain

5.6.1 Inflammatory mechanism

5.6.2 Immunological mechanism

5.6.3 Compressive mechanism

5.6.4 Lumbar spinal stenosis

5.6.5 Skeletal Causes of Radiculopathy

5.6.6 Lumbar bulging or herniated disc

5.7 Prognosis

5.8 Biomarkers for Sciatica

5.9 Diagnosis of Sciatica

5.9.1 Indicators for Sciatica

5.9.2 Imaging

5.9.3 Selective Nerve Root Block (SRNB)

5.10 Differential Diagnosis

5.11 Clinical Guidelines for the Diagnosis for Sciatica

5.11.1 Clinical guideline for diagnosis for General Practice

5.12 Diagnostic algorithm

5.13 Prevention of Sciatica

6 Recognized Establishments

7 Treatment

7.1 Nonsurgical Treatment for Sciatica

7.1.1 Physical therapy

7.1.2 Psychological therapies

7.1.3 Medications

7.2 Surgical Treatment of Sciatica

8 The American College of Physicians (ACP) Guidelines for the Treatment of Low Back Pain

8.1 Grading the Evidence and Developing Recommendations

8.2 Comparative Benefits of Pharmacologic Therapies

8.3 Comparative Benefits of Nonpharmacologic Therapies

8.4 Recommendations

9 The National Institute for Health and Care Excellence (NICE) Treatment Guidelines

10 Epidemiology and Patient Population

10.1 Key Findings

10.2 Epidemiology Methodology

10.3 7MM Total Prevalent Population of Sciatica

11 Country Wise-Epidemiology of Sciatica

11.1 United States

11.1.1 Assumption and Rationale

11.1.2 Prevalence of Sciatica in the United States

11.1.3 Diagnosed Prevalence of Sciatica in the United States

11.1.4 Cause-specific Diagnosed Prevalence of Sciatica in the United States

11.1.5 Gender-specific Diagnosed Prevalence of Sciatica in the United States

11.1.6 Age-specific Diagnosed Prevalence in the United States

11.1.7 Surgery Eligible Patient Pool in the United States

11.2 EU5 Countries

11.2.1 Assumption and Rationale

11.3 Germany

11.3.1 Prevalence of Sciatica in Germany

11.3.2 Diagnosed Prevalence of Sciatica in Germany

11.3.3 Cause-specific Diagnosed Prevalence of Sciatica in Germany

11.3.4 Gender-specific Diagnosed Prevalence of Sciatica in Germany

11.3.5 Age-specific Diagnosed Prevalence in Germany

11.3.6 Surgery Eligible Patient Pool in Germany

11.4 France

11.4.1 Prevalence of Sciatica in France

11.4.2 Diagnosed Prevalence of Sciatica in France

11.4.3 Cause-specific Diagnosed Prevalence of Sciatica in France

11.4.4 Gender-specific Diagnosed Prevalence of Sciatica in France

11.4.5 Age-specific Diagnosed Prevalence in France

11.4.6 Surgery Eligible Patient Pool in France

11.5 Italy

11.5.1 Prevalence of Sciatica in Italy

11.5.2 Diagnosed Prevalence of Sciatica in Italy

11.5.3 Cause-specific Diagnosed Prevalence of Sciatica in Italy

11.5.4 Gender-specific Diagnosed Prevalence of Sciatica in Italy

11.5.5 Age-specific Diagnosed Prevalence in Italy

11.5.6 Surgery Eligible Patient Pool in Italy

11.6 Spain

11.6.1 Prevalence of Sciatica in Spain

11.6.2 Diagnosed Prevalence of Sciatica in Spain

11.6.3 Cause-specific Diagnosed Prevalence of Sciatica in Spain

11.6.4 Gender-specific Diagnosed Prevalence of Sciatica in Spain

11.6.5 Age-specific Diagnosed Prevalence in Spain

11.6.6 Surgery Eligible Patient Pool in Spain

11.7 United Kingdom

11.7.1 Prevalence of Sciatica in the United Kingdom

11.7.2 Diagnosed Prevalence of Sciatica in the United Kingdom

11.7.3 Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom

11.7.4 Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom

11.7.5 Age-specific Diagnosed Prevalence in the United Kingdom

11.7.6 Surgery Eligible Patient Pool in the United Kingdom

11.8 Japan

11.8.1 Assumptions and Rationale

11.8.2 Prevalence of Sciatica in Japan

11.8.3 Diagnosed Prevalence of Sciatica in Japan

11.8.4 Cause-specific Diagnosed Prevalence of Sciatica in Japan

11.8.5 Gender-specific Diagnosed Prevalence of Sciatica in Japan

11.8.6 Age-specific Diagnosed Prevalence in Japan

11.8.7 Surgery Eligible Patient Pool in Japan

12 Appendix

13 DelveInsight Capabilities

14 Disclaimer

15 About DelveInsight

Table 1: Summary of Sciatica, Epidemiology, and Key Events (2017–2030)

Table 2: Non-discogenic causes of Sciatica

Table 3: Physiologic Variants of Sciatica

Table 4: Total Prevalent Population of Sciatica in the 7MM (2017–2030)

Table 5: Prevalence of Sciatica in the United States (2017–2030)

Table 6: Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Table 7: Cause-specific Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Table 8: Gender-specific Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Table 9: Age-specific Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Table 10: Surgery Eligible Patient Pool in the United States (2017–2030)

Table 11: Prevalence of Sciatica in Germany (2017–2030)

Table 12: Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Table 13: Cause-specific Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Table 14: Gender-specific Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Table 15: Age-specific Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Table 16: Surgery Eligible Patient Pool in Germany (2017–2030)

Table 17: Prevalence of Sciatica in France (2017–2030)

Table 18: Diagnosed Prevalence of Sciatica in France (2017–2030)

Table 19: Cause-specific Diagnosed Prevalence of Sciatica in France (2017–2030)

Table 20: Gender-specific Diagnosed Prevalence of Sciatica in France (2017–2030)

Table 21: Age-specific Diagnosed Prevalence of Sciatica in France (2017–2030)

Table 22: Surgery Eligible Patient Pool in France (2017–2030)

Table 23: Prevalence of Sciatica in Italy (2017–2030)

Table 24: Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Table 25: Cause-specific Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Table 26: Gender-specific Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Table 27: Age-specific Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Table 28: Surgery Eligible Patient Pool in Italy (2017–2030)

Table 29: Prevalence of Sciatica in Spain (2017–2030)

Table 30: Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Table 31: Cause-specific Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Table 32: Gender-specific Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Table 33: Age-specific Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Table 34: Surgery Eligible Patient Pool in Spain (2017–2030)

Table 35: Prevalence of Sciatica in the United Kingdom (2017–2030)

Table 36: Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Table 37: Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Table 38: Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Table 39: Age-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Table 40: Surgery Eligible Patient Pool in the United Kingdom (2017–2030)

Table 41: Prevalence of Sciatica in Japan (2017–2030)

Table 42: Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Table 43: Cause-specific Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Table 44: Gender-specific Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Table 45: Age-specific Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Table 46: Surgery Eligible Patient Pool in Japan (2017–2030)



List of Figures:

Figure 1: SWOT Analysis of Sciatica

Figure 2: The sciatic nerve runs from the back, under the buttock, and downward through the hip area into each leg

Figure 3: Types of lumbar disc herniation classification based on the location of the disc herniation relative to the facet joint and spinal canal.

Figure 4: Lumbar spinal stenosis is a common cause of Sciatica

Figure 5: Piriformis Muscles Syndrome

Figure 6: Pathophysiological mechanisms in radicular pain.

Figure 7: Pathoanatomical Features of Degenerative Lumbar Spinal Stenosis

Figure 8: Algorithm for the diagnostic evaluation of patients with low-back pain.

Figure 9: Treatment algorithm of Sciatica

Table 10: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain

Table 11: Adverse events for treatment for Acute, Chronic, and Radicular Low Back Pain

Figure 12: Total Prevalent Population of Sciatica in the 7MM (2017–2030)

Figure 13: Prevalence of Sciatica in the United States (2017–2030)

Figure 14: Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Figure 15: Cause-specific Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Figure 16: Gender-specific Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Figure 17: Age-specific Diagnosed Prevalence of Sciatica in the United States (2017–2030)

Figure 18: Surgery Eligible Patient Pool in the United States (2017–2030)

Figure 19: Prevalence of Sciatica in Germany (2017–2030)

Figure 20: Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Figure 21: Cause-specific Diagnosed Prevalence of Sciatica of Sciatica in Germany (2017–2030)

Figure 22: Gender-specific Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Figure 23: Age-specific Diagnosed Prevalence of Sciatica in Germany (2017–2030)

Figure 24: Surgery Eligible Patient Pool in Germany (2017–2030)

Figure 25: Prevalence of Sciatica in France (2017–2030)

Figure 26: Diagnosed Prevalence of Sciatica in France (2017–2030)

Figure 27: Cause-specific Diagnosed Prevalence of Sciatica in France (2017–2030)

Figure 28: Gender-specific Diagnosed Prevalence of Sciatica in France (2017–2030)

Figure 29: Age-specific Diagnosed Prevalence of Sciatica in France (2017–2030)

Figure 30: Surgery Eligible Patient Pool in France (2017–2030)

Figure 31: Prevalence of Sciatica in Italy (2017–2030)

Figure 32: Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Figure 33: Cause-specific Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Figure 34: Gender-specific Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Figure 35: Age-specific Diagnosed Prevalence of Sciatica in Italy (2017–2030)

Figure 36: Surgery Eligible Patient Pool in Italy (2017–2030)

Figure 37: Prevalence of Sciatica in Spain (2017–2030)

Figure 38: Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Figure 39: Cause-specific Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Figure 40: Gender-specific Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Figure 41: Age-specific Diagnosed Prevalence of Sciatica in Spain (2017–2030)

Figure 42: Surgery Eligible Patient Pool in Spain (2017–2030)

Figure 43: Prevalence of Sciatica in the United Kingdom (2017–2030)

Figure 44: Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Figure 45: Cause-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Figure 46: Gender-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Figure 47: Age-specific Diagnosed Prevalence of Sciatica in the United Kingdom (2017–2030)

Figure 48: Surgery Eligible Patient Pool in the United Kingdom (2017–2030)

Figure 49: Prevalence of Sciatica in Japan (2017–2030)

Figure 50: Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Figure 51: Cause-specific Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Figure 52: Gender-specific Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Figure 53: Age-specific Diagnosed Prevalence of Sciatica in Japan (2017–2030)

Figure 54: Surgery Eligible Patient Pool in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[坐骨神経痛治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆